Molecure S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2017-01-04
Share capital
247,237.86 PLN
Activity description

Molecure is a biotechnology company that discovers and develops first-in-class small-molecule drugs for diseases with significant unmet clinical need. It focuses on unique and unexplored protein targets and has a broad pipeline of drug candidates, including therapies for inflammatory and fibrotic diseases.

Registered address
ul. Żwirki I Wigury 101, 02-089 Warszawa, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-53759-94897-TEIAA-16

Financials

Revenue history (in m)

Filing timeliness

Financial statements were filed on time, on average 25 days early. All were audited by a statutory auditor.

  • 202503/07/2026
  • 202408/07/2025
  • 202318/06/2024
  • 202205/07/2023
  • 202115/07/2022
  • 202014/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 5.47
-0.06 (-1.08%)
5.405.505.4710:0012:0014:0016:00
Open
PLN 5.46
High
PLN 5.55
Low
PLN 5.33
Volume
27.95K
Avg. vol.
37.04K
Market cap
PLN 135.24M
P/E ratio
–
EPS
-PLN 0.45
Shares outstanding
24.72M
52-week
PLN 5.16 – 5.70
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q3 2026USD 178.55kUSD -791.19kUSD -779.58k
Q2 2026USD 378.71kUSD -609.67kUSD -607.78k
Q1 2026USD 32.14kUSD -1.10mUSD -1.10m
Q4 2025USD 642.39kUSD -492.72kUSD -473.13k

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 15%
Top 9.8%
City · Warszawa11,478 / 56,772
Top 20%
Voivodeship · Mazowieckie16,238 / 76,953
Top 21%
Country · Poland63,457 / 297,266
Top 21%

Results vs industry

Revenue
This companyUSD 1.89mMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -3.94mMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 5.80mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 23.72mMedianUSD 281.58kAverageUSD 8.35m

News

Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol (OATD-01 Development Program)

The Independent Data Monitoring Committee (IDMC) recommended continuation of the global Phase II PoC study in patients with active pulmonary sarcoidosis without any changes to the current study protocol. The positive recommendation was issued following the IDMC’s review of the complete safety and efficacy dataset specified for the interim analysis in 30 patients and confirms

Molecure focuses on the most commercially promising projects and closes the RNA program

Molecure is focusing its financial and operational resources on the most promising clinical programs: OATD-01 and OATD-02, as well as on the development of a service using a drug discovery and development tool, co-financed under the FENG program The Company has decided to discontinue the development of the RNA platform and to suspend all research

Invitation to investor meeting 2nd April 2025, 1:00 pm (CET)

Molecure S.A. is pleased to invite you to a meeting dedicated to the presentation of the progress of the ongoing research programmes, in particular clinical trials, as well as the development plans for the next quarters and the discussion of the Company's operational and financial situation for 2024. The meeting will be attended by: –

Molecure (WSE: MOC) and Nasdaq-listed Ocean Biomedical (NASDAQ: OCEA) sign exclusive licensing agreement for development and commercialization of selective YKL-40 inhibitors

This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further

Molecure on the threshold of a breakthrough in treating inflammatory and fibrotic diseases – focus on the most promising therapy and OATD-01 and OATD-02 clinical trial results

Molecure has reduced the number of active projects from seven to five, focusing resources on the most promising assets; Key areas for further development and value building for Molecure are: OATD-01 as a potential breakthrough therapy for the treatment of sarcoidosis and MASH, and OATD-02 in trials in patients with solid tumors. Development of projects

Invitation to investor meeting on 16 October 2024, 10:00 am (CET)

Molecure S.A. is pleased to invite you to a meeting to discuss the Company's operational and financial situation following the publication of its Q3 2024 report, in particular the progress of ongoing clinical and preclinical stage research programs and further plans. The expected time of the meeting is about 90 minutes. The meeting will be

Offer

Websites

The site is available in: Polish and English.

  • molecure.comMolecure
    WordPress 7.1Google AnalyticsGoogle Tag ManagerWPMLApache

Job offers

The company has its own careers page: molecure.com/careers.

Authorized Representatives

Agnieszka Rajczuk-Szczepańska age 55 – Attorney-in-fact (joint)
Barbara Dymek age 41 – Attorney-in-fact (joint)
Marta Grajda age 37 – Attorney-in-fact
Marcin Jan Szumowski age 58 – President of the Management Board
Zbigniew Zasłona age 45 – Management Board Member

Manner of representation

In the case of a one-person management board, the President of the Management Board is authorised to perform legal acts and make declarations on behalf of the company independently. In the case of a multi-member management board, any two members of the management board acting jointly or any member of the management board jointly with a commercial proxy are authorised to perform legal acts and make declarations on behalf of the company.

Supervisory board

Paul Der Horst – Supervisory Board Member
Piotr Lutostański age 48 – Supervisory Board Member
Nancy Van Osselaer – Supervisory Board Member
Paweł Trawkowski age 53 – Supervisory Board Member
Tomasz Piec age 57 – Supervisory Board Member

Beneficial owners

Molecure is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Bank accounts

Registered as a VAT taxpayer on 2012-04-13.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
May 17, 2018Commercial Companies Code notice
Sep 25, 2017Bankruptcy notice

Public aid

20 public aid cases recorded, with a total value of $40,369,134.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$18,750
Aid for research and development projects: industrial research
$6M
Aid for research and development projects: experimental development
$804.6K

European Funds

4 projects recorded: 3 from FE lists ($16,303,134) and 1 Commission grant (FTS) ($705,306).

ProjectEU co-financing
Development of a new service for discovering small-molecule compounds with therapeutic potential using artificial intelligence models
$9M
Preparation of an application for a Eurogrant planned under the EIC Accelerator Open 2025 programme
$17,431
A breakthrough service for discovering new small-molecule drugs targeting mRNA for incurable diseases
$7.3M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
JJP Biologics sp. z o.o.
Captor Therapeutics S.A.
Neuca Clinical Trials Investments sp. z o.o.
Aslab Science P.S.A.
Pikralida sp. z o.o.
Nanogroup S.A.
Bioresearch Group sp. z o.o.
Precisionlife Poland sp. z o.o.
Vasa Therapeutics sp. z o.o.
Medicofarma Biotech S.A.

Change history

DateEvent
2026-05-20Share capital increase
2025-09-01PKD change
2025-05-14Share capital increase
2024-12-24Share capital increase
2023-08-16Share capital increase

FAQ

Last updated: 2026-10-18